Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular ...
Humira (adalimumab) is a long-term maintenance medication used to manage chronic conditions like Crohn’s disease and rheumatoid arthritis. For many people, this drug is not a short-term fix but a ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
UnitedHealth Group, Inc’s. UNH Optum Rx is expanding its offerings for patients with the introduction of two additional HUMIRA biosimilars. Effective Jul 1, Optum Rx will offer three biosimilar ...
VIRGINIA--(BUSINESS WIRE)--Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold ...
AbbVie ABBV expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent in January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results